Applications of peptide hormone ligands for the treatment of dumping and short bowel syndrome - ScienceDirect
Intestinal Adaptation in Short Bowel Syndrome - Jason J. Cisler, Alan L. Buchman, 2005
Review article: a comparison of glucagon‐like peptides 1 and 2 - Janssen - 2013 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome | ACS Pharmacology & Translational Science
![PDF] Synergy of glucagon-like peptide-2 and epidermal growth factor coadministration on intestinal adaptation in neonatal piglets with short bowel syndrome. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/46a296e081b14acd2e895a59805fd3f2aebf185e/3-Figure1-1.png "PDF] Synergy of glucagon-like peptide-2 and epidermal growth factor coadministration on intestinal adaptation in neonatal piglets with short bowel syndrome. | Semantic Scholar")
PDF] Synergy of glucagon-like peptide-2 and epidermal growth factor coadministration on intestinal adaptation in neonatal piglets with short bowel syndrome. | Semantic Scholar
Glucagon-like Peptide 2 (GLP-2) Peptide Molecule. Its Recombinant Analog Teduglutide Is Used To Treat Short-Bowel Syndrome, An Orphan Disease. Cartoon & Wire Representation. Secondary Structure Coloring. Stock Photo, Picture And Royalty Free
Effects of glucagon-like peptide 2 (GLP-2; produced by endocrine L... | Download Scientific Diagram
Short Bowel Syndrome Market to reach US$ 3.66 bn by 2031
Glepaglutide for SBS — Zealand pharma
Short Bowel Syndrome Causes & Treatment | GATTEX® HCP
Glucagon-like peptide 2: an update
JCI Insight - Loss of Glp2r signaling activates hepatic stellate cells and exacerbates diet-induced steatohepatitis in mice
The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome | ACS Pharmacology & Translational Science
Glucagon-like Peptide 2 (GLP-2) Peptide Molecule. Its Recombinant Analog Teduglutide is Used To Treat Short-Bowel Syndrome, an Stock Illustration - Illustration of polymer, magnetic: 187042201
Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology
GLP-2 Agonists for Short Bowel Syndrome - ScienceDirect
Microorganisms | Free Full-Text | GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
dapiglutide (ZP7570) / Zealand Pharma
Gut hormones, and short bowel syndrome: The enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation
Glucagon-Like Peptide-2 - an overview | ScienceDirect Topics
Short Bowel Syndrome Causes & Treatment | GATTEX® HCP
The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome | ACS Pharmacology & Translational Science
GLP-2 | gutsandgrowth
Release of glucagon-like peptide (GLP)-2 by L cells. The L cell... | Download Scientific Diagram
Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology
Glucagon-like Peptide 2 (GLP-2) Peptide Molecule. Its Recombinant Analog Teduglutide is Used To Treat Short-Bowel Syndrome, an Stock Illustration - Illustration of resonance, glucagon: 188454130
Segmental reversal of the distal small intestine in a short bowel syndrome model in piglets showed detrimental effect on weight gain | BMC Gastroenterology | Full Text
